Navigation Links
Premier Biomedical Successfully Advances Cancer Research
Date:12/5/2012

ST. PETERSBURG, Fla., Dec. 5, 2012 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced successful advances in its cancer-focused research.  Researchers successfully killed a cancer tumor in a test tube by simply removing crucial molecular compounds necessary for the cancer's development.  This was accomplished utilizing the Felder Doctrine™: "Physically remove the pathophysiologic basis of the disease." 

Dr. Mitchell S. Felder, Chairman of Premier Biomedical, Inc.'s Scientific Advisory Board, stated: "At best, conventional methods, such as chemotherapy and many current marketed cancer-fighting drugs, can target only one single antigen, thus allowing another antigen to survive the treatment and enabling the cancer to progress.  Plus, these blockers or inhibitors often come with dangerous side effects to the patient.  Premier Biomedical aims for far greater efficacy through mixing and matching multiple cancer target antigens simultaneously.  We actually remove the pathophysiologic basis of the disease – targeting the exact cause of the disease and eliminating it – without dangerous side effects."

Specifically, the researchers removed a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy.  This may open the door to a methodology for eradicating cancer tissue without the use of any other medications and/or procedures that are often accompanied by related side effects.  Further testing has resulted in the successful removal of additional critical cancer-related antigens which are important in the development, growth, and metastasis of cancer tissue.  Leukemia and lymphoma cancers were the focus of these recent successes.

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer.  Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis.  Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania.  The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."  www.premierbiomedicalinc.com

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management.  Actual results could differ materially from current projections or implied results.  Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact

Premier Biomedical, Inc.
William A. Hartman, CEO
(814) 786-8849
info@premierbiomedicalinc.com


'/>"/>
SOURCE Premier Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Ekahau - A Preferred Provider of Real-Time Location Solutions - Is Awarded an Agreement with the Premier Healthcare Alliance
2. Premier Research Expands Salt Lake City and Phoenix Testing Facilities Adding 50% Capacity
3. Premier Wen Visits Asymchems Tianjin Facility
4. Speech and Language Therapy Jobs and Biomedical Science Jobs - Medicspro Leading the way for Medical Recruitment Agencies in the UK
5. Arecor Awarded Biomedical Catalyst Funding Towards £1.3 Million Project
6. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
7. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
8. Dr. Victor Ambros and Dr. Gary Ruvkun Win 2012 Dr. Paul Janssen Award for Biomedical Research for Discovery of MicroRNAs
9. QuantRx® Biomedical Provides Corporate Update: Focused on Diagnostics and Feminine Hygiene Segments
10. Bunker Hill Community College Holds Biomedical Careers Graduation Ceremony
11. Fluke Biomedical training center goes global: adds multi-language support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):